Sodium‐glucose co‐transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2017-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/dom.13003PMID 28477418
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy

  2017cited by this paper
• Sodium‐glucose co‐transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes

  2017cited by this paper
• Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice

  2016cited by this paper
• Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion

  2015influential reference
• The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension.

  2014cited by this paper
• SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.

  2014cited by this paper
• The mechanisms of genome-wide target gene regulation by TCF7L2 in liver cells

  2014cited by this paper
• Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30–50% of Filtered Glucose Load in Humans

  2013cited by this paper
• Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes

  2013cited by this paper
• The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia

  2012cited by this paper
• Why Do SGLT2 Inhibitors Inhibit Only 30–50% of Renal Glucose Reabsorption in Humans?

  2012cited by this paper
• Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Equation Pronouncedly Underestimates Glomerular Filtration Rate in Type 2 Diabetes

  2011influential reference
• Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.

  2011cited by this paper
• Canagliflozin, a novel inhibitor of sodium glucose co‐transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

  2011cited by this paper
• Rapid Upregulation of Sodium-Glucose Transporter SGLT1 in Response to Intestinal Sweet Taste Stimulation

  2010cited by this paper
• Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats.

  2009cited by this paper
• Na(+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity.

  2008cited by this paper
• Active sugar transport in health and disease

  2007cited by this paper
• Effect of Long-Term Type 1 Diabetes on Renal Sodium and Water Transporters in Rats

  2007cited by this paper
• Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes.

  2005cited by this paper
• The sodium/glucose cotransport family SLC5

  2003cited by this paper
• Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes

  2002cited by this paper
• Renal Na(+)-glucose cotransporters.

  2001cited by this paper
• Changes in Sodium or Glucose Filtration Rate Modulate Expression of Glucose Transporters in Renal Proximal Tubular Cells of Rat

  2001cited by this paper
• Overexpression of GLUT2 gene in renal proximal tubules of diabetic Zucker rats.

  1997cited by this paper
• Structure of the human Na+/glucose cotransporter gene SGLT1.

  1994cited by this paper
• Gene expression of epithelial glucose transporters: the role of diabetes mellitus.

  1994cited by this paper
• Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects.

  1971cited by this paper
• Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose.

  1951cited by this paper

• Spatial metabolomics revealed mTOR-mediated gastric epithelial repair by licorice (G. inflata) flavonoids.

  2025cites this paper
• Glucose transporters and their energy homeostasis function in various organs.

  2025cites this paper
• Sodium-glucose transporters SGLT1 and SGLT2 in equine renal, hepatic and pancreatic tissue

  2025cites this paper
• Empagliflozin Mitigates PTZ-Induced Seizures in Rats: Modulating Npas4 and CREB-BDNF Signaling Pathway

  2025cites this paper
• Antin-diabetic cognitive dysfunction effects and underpinning mechanisms of phytogenic bioactive peptides: a review

  2025cites this paper
• NGHIÊN CỨU PHÂN TÍCH TRÌNH TỰ XÁC ĐỊNH ĐỘT BIẾN VÀ MỨC ĐỘ BIỂU HIỆN CỦA GEN NUCB2 VÀ SLC2A2 LIÊN QUAN ĐẾN NỒNG ĐỘ NESFATIN-1 TRÊN BỆNH NHÂN ĐÁI THÁO ĐƯỜNG TÍP 2

  2025cites this paper
• Effects of SGLT2 inhibitors on cognitive impairment in elderly inpatients with heart failure with reduced ejection fraction: a prospective cohort study

  2025cites this paper
• Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2DM and NGT Subjects.

  2024cites this paper
• Peel waste of citrus fruits: A valuable and renewable source of polyphenols for the treatment of diabesity

  2024cites this paper
• Insightful Perspectives on Sodium-glucose Co-transporter 2 Inhibitors: Navigating Safety Updates and Beyond.

  2024cites this paper
• Scraping Therapy Improved Muscle Regeneration through Regulating GLUT4/Glycolytic and AMPK/mTOR/4EBP1 Pathways in Rats with Lumbar Multifidus Injury

  2023cites this paper
• Chemical and Biological Review of Endophytic Fungi Associated with Morus sp. (Moraceae) and In Silico Study of Their Antidiabetic Potential

  2023cites this paper
• 2-Deoxy-glucose ameliorates the peritoneal mesothelial and endothelial barrier function perturbation occurring due to Peritoneal Dialysis fluids exposure.

  2023cites this paper
• SGLT2 Inhibitor Canagliflozin Alleviates High Glucose-Induced Inflammatory Toxicity in BV-2 Microglia

  2023cites this paper
• Research Progress on the Protective Mechanism of Dapagliflozin on Cardiovascular System

  2023cites this paper
• Comparison of SGLT1, SGLT2, and Dual Inhibitor Biological Activity in Treating Type 2 Diabetes Mellitus

  2023cites this paper
• Investigational Agents Targeting SGLT1 and SGLT2 in the Treatment of Type 2 Diabetes Mellitus.

  2023cites this paper
• Insulin-induced mTOR signaling and gluconeogenesis in renal proximal tubules: A mini-review of current evidence and therapeutic potential

  2022cites this paper
• Current Use and Complementary Value of Combining in Vivo Imaging Modalities to Understand the Renoprotective Effects of Sodium-Glucose Cotransporter-2 Inhibitors at a Tissue Level

  2022cites this paper
• Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes

  2022cites this paper
• HNF1A Mutations and Beta Cell Dysfunction in Diabetes

  2022cites this paper
• Decreased expression of Glucagon-like peptide-1 receptor and Sodium-glucose co-transporter 2 in patients with proliferative diabetic retinopathy

  2022cites this paper
• Hypoglycemic bioactivity of anthocyanins: A review on proposed targets and potential signaling pathways

  2022cites this paper
• SGLT-2 inhibitors and nephroprotection in patients with diabetic and non-diabetic chronic kidney disease.

  2022cites this paper
• Renoprotective Mechanism of Sodium-Glucose Cotransporter 2 Inhibitors: Focusing on Renal Hemodynamics

  2022cites this paper
• Sodium-glucose Cotransporter Type 2 Inhibitors: A New Insight into the Molecular Mechanisms of Diabetic Nephropathy.

  2022cites this paper
• Col4a3-/- Mice on Balb/C Background Have Less Severe Cardiorespiratory Phenotype and SGLT2 Over-Expression Compared to 129x1/SvJ and C57Bl/6 Backgrounds

  2022cites this paper
• Glycaemia dynamics concepts before and after insulin.

  2022influential citation
• Effects of Gastric Bypass Surgery on Glucose Transporter Expression and Fibrotic Biomarkers in Kidney of Diabetic Fatty Rats

  2021cites this paper
• Renal Tubular Handling of Glucose and Fructose in Health and Disease.

  2021cites this paper
• Human Glucose Transporters in Renal Glucose Homeostasis

  2021cites this paper
• Sodium-Glucose Cotransporter-2 Inhibitors: Heart Failure and Renal Protection Indications

  2021cites this paper
• A New Hope in Type 2 Diabetes Mellitus Management: Sodium-Glucose Cotransporter 2 Inhibitors

  2021cites this paper
• Renoprotection with sodium‐glucose cotransporter‐2 inhibitors in children: Knowns and unknowns

  2021cites this paper
• Renal lipid accumulation induced by high-fat diet regulates glucose homeostasis via sodium-glucose cotransporter 2.

  2021cites this paper
• Potential impacts of diabetes mellitus and anti-diabetes agents on expressions of sodium-glucose transporters (SGLTs) in mice

  2021cites this paper
• Uncurtaining the pivotal role of ABC transporters in diabetes mellitus

  2021cites this paper
• Diabetes and Cardiovascular Risk in Renal Transplant Patients

  2021cites this paper
• Pathogenesis of diabesity‐induced kidney disease: role of kidney nutrient sensing

  2021cites this paper
• Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors

  2021cites this paper
• SGLT2 Inhibitors: A Novel Player in the Treatment and Prevention of Diabetic Cardiomyopathy

  2020cites this paper
• Systematic review on anti-diabetic properties of chalcones.

  2020cites this paper
• Effect of Insulin on Proximal Tubules Handling of Glucose: A Systematic Review

  2020cites this paper
• Glucose transporters in the kidney in health and disease

  2020cites this paper
• Functional Expression of Sodium-Dependent Glucose Transporter in Amelogenesis

  2020cites this paper
• SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?

  2020cites this paper
• Insulin enhances renal glucose excretion: relation to insulin sensitivity and sodium-glucose cotransport

  2020cites this paper
• Mechanisms of Sodium–Glucose Cotransporter 2 Inhibition: Insights From Large-Scale Proteomics

  2020cites this paper
• Effects of gastric bypass surgery on expression of glucose transporters and fibrotic biomarkers in kidney of diabetic fatty rats.

  2020cites this paper
• A common glomerular transcriptomic signature distinguishes diabetic kidney disease from other kidney diseases in humans and mice.

  2020cites this paper
• Expression of glucose transporters in duodenal mucosa of patients with type 1 diabetes

  2020cites this paper
• Sodium-glucose co-transporter-2 inhibitors: peculiar "hybrid" diuretics that protect from target organ damage and cardiovascular events.

  2020cites this paper
• SGLT-2 inhibitors and nephroprotection: current evidence and future perspectives

  2020cites this paper
• Marein ameliorates diabetic nephropathy by inhibiting renal sodium glucose transporter 2 and activating the AMPK signaling pathway in db/db mice and high glucose-treated HK-2 cells.

  2020cites this paper
• Taxifolin improves disorders of glucose metabolism and water-salt metabolism in kidney via PI3K/AKT signaling pathway in metabolic syndrome rats.

  2020cites this paper
• Immunohistochemical expressionof sodium-dependent glucose transporter - 2 (SGLT-2) in clear cell renal carcinoma: possible prognostic implications

  2019cites this paper
• Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors

  2019cites this paper
• Renal SGLT mRNA Expression in Human Health and Disease: A Study in Two Cohorts.

  2019cites this paper
• Advances and potential of gene therapy for type 2 diabetes mellitus

  2019cites this paper
• 17β-Estradiol Regulates Glucose Metabolism and Insulin Secretion in Rat Islet β Cells Through GPER and Akt/mTOR/GLUT2 Pathway

  2019cites this paper
• Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.

  2019cites this paper
• SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects

  2019cites this paper
• The effect of SGLT-2 inhibitors on blood pressure: a pleiotropic action favoring cardio- and nephroprotection.

  2019cites this paper
• A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium‐glucose co‐transporter‐2 inhibitors

  2019cites this paper
• What does sodium‐glucose co‐transporter 1 inhibition add: Prospects for dual inhibition

  2019cites this paper
• SGLT2 inhibition to address the unmet needs in diabetic nephropathy

  2019cites this paper
• The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials.

  2019cites this paper
• Renal Specific RNAi Delivery by Fibrillar Nanoparticle Excipients

  2019cites this paper
• Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease

  2019cites this paper
• (‐)‐Epicatechin and the Colonic 2,3‐Dihydroxybenzoic Acid Metabolite Regulate Glucose Uptake, Glucose Production, and Improve Insulin Signaling in Renal NRK‐52E Cells

  2018cites this paper
• Sodium glucose cotransporter (SGLT)‐2 inhibitors: Do we need them for glucose‐lowering, for cardiorenal protection or both?

  2018cites this paper
• Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure

  2018cites this paper
• SGLT1 inhibition: Pros and cons

  2018cites this paper
• Protective effects of (-)-epicatechin and the colonic metabolite 3,4-dihydroxyphenylacetic acid against glucotoxicity-induced insulin signalling blockade and altered glucose uptake and production in renal tubular NRK-52E cells.

  2018cites this paper
• SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.

  2018cites this paper
• Potent Sodium/Glucose Cotransporter SGLT1/2 Dual Inhibition Improves Glycemic Control Without Marked Gastrointestinal Adaptation or Colonic Microbiota Changes in Rodents

  2018cites this paper
• The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus

  2018cites this paper
• Cardiac effects of SGLT2 inhibitors: the sodium hypothesis

  2018cites this paper
• Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.

  2018cites this paper
• SGLT1 and SGLT1 Inhibitors: A Role to Be Assessed in the Current Clinical Practice

  2017cites this paper
• Glucose and Lipid Transporters Roles in Type 2 Diabetes

  2017influential citation